115 related articles for article (PubMed ID: 20944137)
1. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
2. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
3. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Ling YH; Zou Y; Perez-Soler R
Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
[TBL] [Abstract][Full Text] [Related]
4. Influence of p53 expression on sensitivity of cancer cells to bleomycin.
Lee YS; Yoon S; Park MS; Kim JH; Lee JH; Song CW
J Biochem Mol Toxicol; 2010; 24(4):260-9. PubMed ID: 20135637
[TBL] [Abstract][Full Text] [Related]
5. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
6. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
Riva CM
Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
[TBL] [Abstract][Full Text] [Related]
7. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
Wang WD; Li R; Chen ZT; Li DZ; Duan YZ; Cao ZH
Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
[TBL] [Abstract][Full Text] [Related]
10. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
11. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
Wang JL; Jiao SC; Ye P; Li JY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):770-3. PubMed ID: 18504201
[TBL] [Abstract][Full Text] [Related]
12. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
14. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Li YX; Lin ZB; Tan HR
Acta Pharmacol Sin; 2004 Jan; 25(1):76-82. PubMed ID: 14704126
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells.
Horio Y; Hasegawa Y; Sekido Y; Takahashi M; Roth JA; Shimokata K
Cancer Gene Ther; 2000 Apr; 7(4):537-44. PubMed ID: 10811471
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
17. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
18. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.
Rohr UP; Wulf MA; Stahn S; Heyd F; Steidl U; Fenk R; Opalka B; Pitschke G; Prisack HB; Bojar H; Haas R; Kronenwett R
Cancer Gene Ther; 2003 Dec; 10(12):898-906. PubMed ID: 14712316
[TBL] [Abstract][Full Text] [Related]
19. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.
Breen L; Heenan M; Amberger-Murphy V; Clynes M
Anticancer Res; 2007; 27(3A):1361-4. PubMed ID: 17593631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]